CO2023011603A2 - Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial - Google Patents

Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial

Info

Publication number
CO2023011603A2
CO2023011603A2 CONC2023/0011603A CO2023011603A CO2023011603A2 CO 2023011603 A2 CO2023011603 A2 CO 2023011603A2 CO 2023011603 A CO2023011603 A CO 2023011603A CO 2023011603 A2 CO2023011603 A2 CO 2023011603A2
Authority
CO
Colombia
Prior art keywords
api5
recombinant
proteins
application
apoptosis inhibitor
Prior art date
Application number
CONC2023/0011603A
Other languages
English (en)
Inventor
Kenneth Cadwell
Shohei Koide
Yu Matsuzawa-Ishimoto
Akiko Koide
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of CO2023011603A2 publication Critical patent/CO2023011603A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona, entre otras cosas, proteínas API5 recombinantes y ácidos nucleicos aislados que las codifican. También se proporcionan vectores que comprenden los ácidos nucleicos y células hospedadoras que comprenden los vectores o ácidos nucleicos que codifican las proteínas API5 recombinantes. Además, se proporcionan composiciones que comprenden dichas proteínas recombinantes, y métodos de uso de estas proteínas recombinantes para la restitución epitelial y el tratamiento de enfermedades y trastornos relacionados.
CONC2023/0011603A 2021-03-05 2023-08-31 Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial CO2023011603A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163157225P 2021-03-05 2021-03-05
PCT/US2022/019138 WO2022187738A1 (en) 2021-03-05 2022-03-07 Application of apoptosis inhibitor 5 (api5) for epithelial restitution

Publications (1)

Publication Number Publication Date
CO2023011603A2 true CO2023011603A2 (es) 2023-09-18

Family

ID=83154664

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0011603A CO2023011603A2 (es) 2021-03-05 2023-08-31 Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial

Country Status (9)

Country Link
EP (1) EP4301471A1 (es)
JP (1) JP2024509540A (es)
CN (1) CN118159569A (es)
AU (1) AU2022229921A1 (es)
BR (1) BR112023017843A2 (es)
CA (1) CA3210274A1 (es)
CO (1) CO2023011603A2 (es)
MX (1) MX2023010078A (es)
WO (1) WO2022187738A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076309B2 (en) * 2008-04-30 2011-12-13 New York University USP47 inhibtors and methods to induce apoptosis
CA2938470C (en) * 2014-02-17 2022-08-30 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antiapoptotic protein aac-11 derived peptides for the treatment of cancer
US20160202242A1 (en) * 2014-12-26 2016-07-14 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth

Also Published As

Publication number Publication date
EP4301471A1 (en) 2024-01-10
CA3210274A1 (en) 2022-09-09
WO2022187738A1 (en) 2022-09-09
AU2022229921A1 (en) 2023-09-14
JP2024509540A (ja) 2024-03-04
MX2023010078A (es) 2023-11-09
CN118159569A (zh) 2024-06-07
BR112023017843A2 (pt) 2023-12-05

Similar Documents

Publication Publication Date Title
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
ECSP22063238A (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
AR115389A1 (es) Anticuerpo antagonista de cd73
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CO2020003187A2 (es) Rnai variante
EA202092459A1 (ru) Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
CR20170507A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
CO2023011603A2 (es) Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial
MX2020003672A (es) Proteinas de fusion inmunomoduladora.
BR112022006842A2 (pt) Construtos de igf2 variante
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
BR112022006923A2 (pt) Polipeptídeos recombinantes para localização celular regulável
BR112023003265A2 (pt) Inibidores de secreção de proteínas
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)
AR120358A1 (es) Proteínas cdkl5 recombinantes, terapia génica y métodos de producción